RGNT
Regentis Biomaterials Ltd.
Healthcare — Medical Instruments & Supplies
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
None
1 analysts
$1.82
+$0.01 (+0.55%)
Target:
$10.00
(449.5%)
Price History
52-Week Range
Sign in to add RGNT to a watchlist or set price alerts.
Fundamentals
| Market Cap | $32.16M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-24.16 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 25.23 |
| Recommendation | None |
| Analyst Target | $10.00 |
| Analysts | 1 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 59.1 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $15.50 |
| 52-Week Low | $1.23 |
| 50-Day Avg | $2.83 |
| 200-Day Avg | $4.22 |
| Avg Volume | $5.36M |
| Volume | 157.8K |
Performance Analysis
BULLISHRGNT shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($1.23), which could present a value opportunity.
+
RSI at 59.1 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none" from 1 analysts.
+
Average analyst target of $10.00 implies 449.5% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:29 UTC
Back to Screener Export Report